JP2017501143A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017501143A5 JP2017501143A5 JP2016536812A JP2016536812A JP2017501143A5 JP 2017501143 A5 JP2017501143 A5 JP 2017501143A5 JP 2016536812 A JP2016536812 A JP 2016536812A JP 2016536812 A JP2016536812 A JP 2016536812A JP 2017501143 A5 JP2017501143 A5 JP 2017501143A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- car
- region
- sequence
- tslpr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 13
- 239000000427 antigen Substances 0.000 claims 6
- 102000038129 antigens Human genes 0.000 claims 6
- 108091007172 antigens Proteins 0.000 claims 6
- 102100005170 CRLF2 Human genes 0.000 claims 5
- 101700020064 CRLF2 Proteins 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 230000003834 intracellular Effects 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 230000011664 signaling Effects 0.000 claims 4
- 102100008191 CD8A Human genes 0.000 claims 3
- 101700054655 CD8A Proteins 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 230000002062 proliferating Effects 0.000 claims 3
- 239000012472 biological sample Substances 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 2
- 101700058737 IKZF Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 1
- 239000012491 analyte Substances 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Claims (10)
- TSLPRに特異的な抗原結合領域、膜貫通領域、及び細胞内T細胞シグナル伝達領域を含むキメラ抗原受容体(CAR)であって、ここで、前記抗原結合領域が軽鎖可変領域を含み、該軽鎖可変領域が、配列番号18、20、22、24、25、27、及び29の配列、又は配列番号19、21、23、24、26、28、及び29の配列を含む、CAR。
- TSLPRに特異的な抗原結合領域、膜貫通領域、及び細胞内T細胞シグナル伝達領域を含むキメラ抗原受容体(CAR)であって、ここで、前記抗原結合領域が重鎖可変領域を含み、該重鎖可変領域が、配列番号6、7、9、10、11、13、及び15の配列、又は配列番号6、8、9、10、12、14、及び16の配列を含む、CAR。
- 前記抗原結合領域が配列番号1を含む、請求項1又は2に記載のCAR。
- 前記膜貫通領域がCD8アミノ酸配列を含み、該CD8アミノ酸配列が配列番号35のCD8αヒンジ配列と配列番号36の配列の膜貫通領域とを含み、前記細胞内T細胞シグナル伝達領域が、配列番号37の4-1BBアミノ酸配列を含み、且つ、前記細胞内T細胞シグナル伝達領域が、配列番号38のCD3ゼータアミノ酸配列を含む、請求項1〜3のいずれか1項に記載のCAR。
- 前記CARが、配列番号39〜46の配列のいずれか1を含む、請求項1に記載のCAR。
- 請求項1〜5のいずれか1項に記載のCARをコードするヌクレオチド配列を含む核酸。
- 被検体におけるガンの存在を検出する方法であって、該方法が、
(a) 請求項1〜5のいずれか1項のCAR、又は請求項6に記載の核酸と該被検体由来の1以上の細胞を含む試料を接触させて、それによって複合体を形成させること、及び
(b)前記複合体を検出すること
を含み、前記複合体の検出がガンの存在を示す方法。 - 請求項1〜5のいずれか1項に記載のCAR、又は、請求項6に記載の核酸を含む、哺乳動物のガンの治療又は予防用医薬組成物。
- 請求項1〜5のいずれか1項に記載のCAR、又は、請求項16に記載の核酸を含む、哺乳動物におけるIKZF遺伝子の突然変異に関連している増殖性疾患の治療又は予防用医薬組成物。
- 増殖性疾患のある被検体が、請求項1又は2に記載のTSLPRに特異的な抗原結合領域を含むキメラ抗原受容体を用いる治療の候補であるか否かを決定するための情報を収集するための方法であって、該方法が、前記被検体からの生体試料中のTSLPR発現レベルを測定することと、前記生体試料の前記TSLPR発現レベルが、前記増殖性疾患のない対照被検体からの試料と比べて、増加しているか否かを決定することとを含む、方法。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021086485A JP7100177B2 (ja) | 2013-12-06 | 2021-05-21 | 胸腺間質性リンパ球新生因子受容体特異的キメラ抗原受容体及びそれを使用する方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361912948P | 2013-12-06 | 2013-12-06 | |
| US61/912,948 | 2013-12-06 | ||
| US201461991697P | 2014-05-12 | 2014-05-12 | |
| US61/991,697 | 2014-05-12 | ||
| PCT/US2014/063096 WO2015084513A1 (en) | 2013-12-06 | 2014-10-30 | Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021086485A Division JP7100177B2 (ja) | 2013-12-06 | 2021-05-21 | 胸腺間質性リンパ球新生因子受容体特異的キメラ抗原受容体及びそれを使用する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017501143A JP2017501143A (ja) | 2017-01-12 |
| JP2017501143A5 true JP2017501143A5 (ja) | 2017-11-30 |
| JP6943568B2 JP6943568B2 (ja) | 2021-10-06 |
Family
ID=51946020
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016536812A Active JP6943568B2 (ja) | 2013-12-06 | 2014-10-30 | 胸腺間質性リンパ球新生因子受容体特異的キメラ抗原受容体及びそれを使用する方法 |
| JP2021086485A Active JP7100177B2 (ja) | 2013-12-06 | 2021-05-21 | 胸腺間質性リンパ球新生因子受容体特異的キメラ抗原受容体及びそれを使用する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021086485A Active JP7100177B2 (ja) | 2013-12-06 | 2021-05-21 | 胸腺間質性リンパ球新生因子受容体特異的キメラ抗原受容体及びそれを使用する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10676528B2 (ja) |
| EP (1) | EP3077416B1 (ja) |
| JP (2) | JP6943568B2 (ja) |
| CN (1) | CN105899531B (ja) |
| CA (1) | CA2932424C (ja) |
| RU (1) | RU2701346C1 (ja) |
| SG (1) | SG11201604565WA (ja) |
| WO (1) | WO2015084513A1 (ja) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11299546B2 (en) | 2016-05-27 | 2022-04-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | FLT3-specific chimeric antigen receptors and methods using same |
| EP3507304B1 (en) | 2016-09-02 | 2024-04-03 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with duocars |
| EP3606548A4 (en) * | 2017-04-04 | 2021-03-24 | Loma Linda University | BIOLOGICAL PREPARATION FOR TREATMENT OF CANCER |
| CN111629735B (zh) * | 2017-10-16 | 2024-05-17 | 莱蒂恩技术公司 | 用于用抗cd22免疫治疗来治疗癌症的组合物和方法 |
| CN110526985A (zh) * | 2018-05-25 | 2019-12-03 | 深圳宾德生物技术有限公司 | 一种靶向egfr的嵌合抗原受体、嵌合抗原受体t细胞及其制备方法和应用 |
| CN111632135A (zh) * | 2020-05-09 | 2020-09-08 | 深圳宾德生物技术有限公司 | 靶向nkg2d的嵌合抗原受体t细胞在治疗前列腺癌中的应用、治疗前列腺癌的药物 |
| JP2023530997A (ja) * | 2020-06-19 | 2023-07-20 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | Ｂｓｔ２ロングアイソフォームを標的化する抗ｂｓｔ２抗体 |
| CA3171101A1 (en) * | 2020-06-22 | 2021-12-30 | Dina SCHNEIDER | Compositions and methods for treating cancer with tslpr-cd19 or tslpr-cd22 immunotherapy |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| WO2023028612A2 (en) * | 2021-08-27 | 2023-03-02 | Board Of Regents, The University Of Texas System | Anti-tslpr (crlf2) antibodies |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US3832253A (en) | 1973-03-21 | 1974-08-27 | Baxter Laboratories Inc | Method of making an inflatable balloon catheter |
| US4450150A (en) | 1973-05-17 | 1984-05-22 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery depots, and method for preparing and using the same |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4667014A (en) | 1983-03-07 | 1987-05-19 | Syntex (U.S.A.) Inc. | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| CA1200416A (en) | 1983-05-13 | 1986-02-11 | Societe Des Produits Nestle S.A. | Food process |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| IN165717B (ja) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| DK0814159T3 (da) | 1990-08-29 | 2005-10-24 | Genpharm Int | Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
| JPH04167172A (ja) | 1990-10-31 | 1992-06-15 | Nec Corp | ベクトルプロセッサ |
| JP3266311B2 (ja) | 1991-05-02 | 2002-03-18 | 生化学工業株式会社 | 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤 |
| US8211422B2 (en) | 1992-03-18 | 2012-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric receptor genes and cells transformed therewith |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| JP2004511425A (ja) | 2000-02-08 | 2004-04-15 | ザ ペン ステート リサーチ ファウンデーション | 免疫療法に使用されるインターロイキン１３受容体サブユニットアルファー２ |
| EP2077279B1 (en) | 2000-06-28 | 2012-09-05 | Amgen Inc. | Thymic stromal lymphopoietin receptor molecules and uses thereof |
| GB0603683D0 (en) * | 2006-02-23 | 2006-04-05 | Novartis Ag | Organic compounds |
| WO2008045437A2 (en) | 2006-10-09 | 2008-04-17 | The General Hospital Corporation | Chimeric t-cell receptors and t-cells targeting egfrviii on tumors |
| JP5059119B2 (ja) | 2006-12-14 | 2012-10-24 | シェーリング コーポレイション | 操作された抗ｔｓｌｐ抗体 |
| MX2010008688A (es) * | 2008-02-07 | 2010-08-30 | Schering Corp | Anticuerpos anti-receptor de linfopoyetina estromal timica procesados por ingenieria. |
| CA2768552A1 (en) * | 2009-07-31 | 2011-02-03 | President And Fellows Of Harvard College | Programming of cells for tolerogenic therapies |
| WO2012007495A1 (en) | 2010-07-15 | 2012-01-19 | F. Hoffmann-La Roche Ag | Antibodies specifically binding to human tslpr and methods of use |
| KR102243575B1 (ko) | 2010-12-09 | 2021-04-22 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도 |
| WO2013103614A1 (en) | 2011-12-30 | 2013-07-11 | Stc.Unm | Crlf-2 binding peptides, protocells and viral-like particles useful in the treatment of cancer, including acute lymphoblastic leukemia (all) |
| WO2013105089A2 (en) | 2012-01-09 | 2013-07-18 | Yada Research And Development Co. Ltd. | Anti-inflammatory peptides and use thereof |
| ES2774160T3 (es) * | 2012-02-13 | 2020-07-17 | Seattle Childrens Hospital D/B/A Seattle Childrens Res Institute | Receptores de antígenos quiméricos biespecíficos y usos terapéuticos de los mismos |
| DK2906684T3 (da) * | 2012-10-10 | 2020-09-28 | Sangamo Therapeutics Inc | T-celle-modificerende forbindelser og anvendelser deraf |
| KR102313997B1 (ko) * | 2013-02-20 | 2021-10-20 | 노파르티스 아게 | 인간화 항-EGFRvIII 키메라 항원 수용체를 사용한 암의 치료 |
| EP3858379A1 (en) | 2013-11-21 | 2021-08-04 | Autolus Limited | Cell |
| WO2015118124A1 (en) * | 2014-02-06 | 2015-08-13 | Vib Vzw | Thymic stromal lymphopoietin receptor antagonist |
| EP3507304B1 (en) | 2016-09-02 | 2024-04-03 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with duocars |
-
2014
- 2014-10-30 CA CA2932424A patent/CA2932424C/en active Active
- 2014-10-30 WO PCT/US2014/063096 patent/WO2015084513A1/en active Application Filing
- 2014-10-30 US US15/101,583 patent/US10676528B2/en active Active
- 2014-10-30 CN CN201480072437.4A patent/CN105899531B/zh active Active
- 2014-10-30 SG SG11201604565WA patent/SG11201604565WA/en unknown
- 2014-10-30 RU RU2016124670A patent/RU2701346C1/ru active
- 2014-10-30 JP JP2016536812A patent/JP6943568B2/ja active Active
- 2014-10-30 EP EP14802259.3A patent/EP3077416B1/en active Active
-
2020
- 2020-04-28 US US16/860,216 patent/US11834509B2/en active Active
-
2021
- 2021-05-21 JP JP2021086485A patent/JP7100177B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017501143A5 (ja) | ||
| Yamauchi et al. | T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors | |
| JP2018519508A5 (ja) | ||
| Rich et al. | Survey of the year 2006 commercial optical biosensor literature | |
| Cao et al. | B. 1.1. 529 escapes the majority of SARS-CoV-2 neutralizing antibodies of diverse epitopes | |
| RU2016124670A (ru) | Химерные антигенные рецепторы, специфичные в отношении рецептора тимусного стромального лимфопоэтина, и способы их применения | |
| Poole et al. | Therapeutic high affinity T cell receptor targeting a KRASG12D cancer neoantigen | |
| FI3332006T3 (fi) | Uusia anti-PD-L1-vasta-aineita | |
| Mehta et al. | An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA | |
| WO2017192924A1 (en) | Cell-based neoantigen vaccines and uses thereof | |
| Liu et al. | Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer | |
| JP2016516735A5 (ja) | ||
| JP2008535477A5 (ja) | ||
| JP2020522261A5 (ja) | ||
| JP2017504324A5 (ja) | ||
| RU2017107773A (ru) | Антитела, специфичные к ммр9 | |
| Klebanoff et al. | T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome | |
| JP2015517982A5 (ja) | ||
| JP2018528773A5 (ja) | ||
| JP2017538412A5 (ja) | ||
| JP2022524216A (ja) | 持続的臨床効果のがんバイオマーカー | |
| MX358772B (es) | Metodo para detectar cancer. | |
| EP3538891A2 (en) | Compositions and methods for the simultaneous genomic, transcriptomic and proteomic analysis of single cells | |
| JP2014529297A (ja) | 新規な抗ｃｘｃｒ４抗体並びに癌の検出および診断のためのその使用 | |
| BR112015001102A2 (ja) | A detecting method of cancer |